The Enduring Success of Hybridoma-based Antibody Development
White Paper Aug 14, 2019
Since its original development in 1975, hybridoma technology encourages researchers all over the world to share their antibodies with one another, unlocking a vast amount of potential for biological research.
Due to their high selectivity, monoclonal antibodies (mAbs) are used in a wide range of disciplines, including research, diagnostics and therapeutic applications. Despite the advancement of modern antibody generation technologies, hybridoma-based antibody production continues to be a leading approach for mAb discovery and development.
Download these whitepapers to explore:
- The key benefits of using hybridoma-based antibody development
- Perceived misconceptions relating to hybridoma technology
- Alternative approaches that currently exist for mAb generation
Related White Papers
Download this compendium to learn more about fragment analyzers and how these are applied to workflows.
READ MOREDownload this case study to learn more about how Thermo Scientific Core LIMS™ and Core ELN™ software solutions are supporting efforts to develop the human microbiome into a new modality for drug development.
READ MOREDownload this whitepaper to learn more about next-generation sequencing and factors involved in probe designing.
READ MORELike what you just read? You can find similar content on the communities below.
Biopharma Cell Science Immunology & MicrobiologyTo personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free
LOGIN SUBSCRIBE FOR FREE
